Specialty R&D psychedelics company PharmaDrug Inc. (OTCQB:LMLLF) has inked a research collaboration agreement with PharmaTher Holdings Ltd. (OTC:PHRRF) to evaluate the delivery of DMT through PharmaTher's microneedle patch technology.
PharmaDrug has said that the DMT microneedle patch may enable flexible drug load capacity and combinations, controlled release delivery and potentially hold pharmacokinetic and safety profiles, overcoming obstacles associated with oral dosing.
Chairman and CEO Daniel Cohen noted that both companies' combined programs and expertise in drug delivery and pharmacology, specifically relating to DMT, "set the stage for the potential development of new treatment options for mental health conditions."
Results from PharmaTher and partner Terasaki Institute for Biomedical Innovation (TIBI)'s non-clinical study on the DMT microneedle patch will be available in early Q2 2023 and will be used to support a potential human clinical trial.
Further, following this study's outcomes PharmaDrug and PharmaTher will set a product and clinical development plan to commence regulatory discussions toward clinical studies in several indications where DMT holds promise.
See also: MDMA News: Optimi's New Drug Now Available, Revive Advances Transdermal Patch Evaluations
PharmaDrug has several psychedelic-related programs, including the discovery of a novel DMT analog and delivery device for the treatment of primary open-angle glaucoma with partner TIBI; the advancement of a DMT clinical research collaboration with Johns Hopkins University and the completion of foundational research on the role of endogenous DMT with the University of Michigan.
Photo: Benzinga edit with photo by aiyoshi597, Gisele Yashar, Bacsica and Gorodenkoff on Shutterstock.
专业研发迷幻药公司PharmaDrug Inc.(场外交易代码:LMLLF)与PharmaTher控股有限公司(场外交易代码:PHRRF)签署了一项研究合作协议,以评估通过PharmaTher的微针贴片技术交付DMT的情况。
PharmaDrug公司表示,DMT微针贴片可以实现灵活的药物装载能力和组合、受控释放,并可能保持药代动力学和安全性,克服与口服剂量相关的障碍。
董事长兼首席执行官Daniel·科恩指出,两家公司在药物输送和药理学方面的联合项目和专业知识,特别是与DMT相关的项目和专业知识,为潜在开发新的精神健康疾病治疗方案奠定了基础。
PharmaTher及其合作伙伴Terasaki生物医学创新研究所(TIBI)对DMT微针贴片的非临床研究结果将于2023年第二季度初公布,并将用于支持潜在的人体临床试验。
此外,根据这项研究的结果,PharmaDrug和PharmaTher将制定一项产品和临床开发计划,开始对DMT有希望的几种适应症的临床研究进行监管讨论。
另见:MDMA新闻:Optimi的新药现已上市,恢复先进的经皮贴片评估
PharmaDrug有几个与迷幻相关的项目,包括与合作伙伴Tibi发现一种用于治疗原发性开角型青光眼的新型DMT类似物和输送设备;与约翰·霍普金斯大学的DMT临床研究合作取得进展,与密歇根大学完成关于内源性DMT作用的基础研究。
照片:Benzinga编辑与Shutterstock上的aiyoshi597,Gisele Yashar,Bacsica和Gorodenkoff的照片。